
Vivian Adamski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10665150/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Establishment of a glioblastoma in vitro (in)complete resection dual co-culture model suitable for drug testing. Annals of Anatomy, 2020, 228, 151440.	1.9	10
2	Combined treatment of AT101 and demethoxycurcumin yields an enhanced anti-proliferative effect in human primary glioblastoma cells. Journal of Cancer Research and Clinical Oncology, 2020, 146, 117-126.	2.5	10
3	<p>AT101-Loaded Cubosomes as an Alternative for Improved Glioblastoma Therapy</p> . International Journal of Nanomedicine, 2020, Volume 15, 7415-7431.	6.7	44
4	Entry and exit of chemotherapeutically-promoted cellular dormancy in glioblastoma cells is differentially affected by the chemokines CXCL12, CXCL16, and CX3CL1. Oncogene, 2020, 39, 4421-4435.	5.9	23
5	Macroscopic Silicone Microchannel Matrix for Tailored Drug Release and Localized Glioblastoma Therapy. ACS Biomaterials Science and Engineering, 2020, 6, 3388-3397.	5.2	12
6	Dormancy and NKG2D system in brain�metastases: Analysis of immunogenicity. International Journal of Molecular Medicine, 2020, 45, 298-314.	4.0	5
7	NKG2D ligands in glioma stem-like cells: expression in situ and in vitro. Histochemistry and Cell Biology, 2018, 149, 219-233.	1.7	27
8	Effects of sequentially applied single and combined temozolomide, hydroxychloroquine and AT101 treatment in a long-term stimulation glioblastoma in vitro model. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1475-1485.	2.5	15
9	The Chemokine Receptor CXCR6 Evokes Reverse Signaling via the Transmembrane Chemokine CXCL16. International Journal of Molecular Sciences, 2017, 18, 1468.	4.1	10
10	Isolation and Characterization of Fast-Migrating Human Glioma Cells in the Progression of Malignant Gliomas. Oncology Research, 2017, 25, 341-353.	1.5	10
11	Dormant glioblastoma cells acquire stem cell characteristics and are differentially affected by Temozolomide and AT101 treatment. Oncotarget, 2017, 8, 108064-108078.	1.8	33